Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech), serving hospitals, physicians, and patients globally. Investors research JNJ for its dividend history, portfolio of branded drugs and surgical products, and position in defensive healthcare sectors.
Get a full AI research report on JNJ
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Johnson & Johnson do?
JNJ generates revenue through two primary segments: Innovative Medicine, which develops and sells prescription drugs for oncology, immunology, neuroscience, and infectious diseases; and MedTech, which manufactures surgical instruments, orthopedic implants, cardiovascular devices, and vision products sold to hospitals and healthcare professionals. The company operates a vertically integrated model spanning R&D, manufacturing, and direct distribution through wholesalers and retailers. With a gross margin of 68%, JNJ demonstrates pricing power and operational efficiency typical of established pharmaceutical and device manufacturers.
Bull case
- ✓Operating margin of 27.4% and net margin of 21.8% reflect strong pricing power and cost control in mature pharmaceutical and device markets.
- ✓Dividend yield of 2.04% with a 60% payout ratio provides current income while retaining capital for R&D and acquisitions, a hallmark of JNJ's shareholder model.
- ✓Diversified revenue across two segments (pharma and devices) and multiple therapeutic areas reduces dependence on any single product or market.
- ✓Return on equity of 26.4% indicates efficient capital deployment and value creation relative to shareholder capital.
- ✓Established brand portfolio and regulatory approvals create barriers to entry and support pricing stability in prescription and surgical markets.
Bear case
- ✗Forward P/E of 20.7 and trailing P/E of 30.5 suggest the stock is priced at a premium relative to historical averages and broader market multiples, limiting margin of safety.
- ✗PEG ratio of 4.88 indicates valuation may not fully reflect near-term earnings growth, raising questions about growth justification at current prices.
- ✗Debt-to-equity ratio of 67.7% reflects significant leverage, which constrains financial flexibility and increases refinancing risk in a rising-rate environment.
- ✗Quick ratio of 0.689 suggests potential short-term liquidity constraints if operational cash flow deteriorates or debt matures unexpectedly.
- ✗Patent expirations on key drugs and competitive generic/biosimilar pressure in the pharmaceutical segment pose ongoing revenue headwinds.
JNJ valuation & financial health
JNJ trades at a trailing P/E of 30.5 and forward P/E of 20.7, reflecting a valuation premium typical of large-cap defensive healthcare stocks. The company's profitability metrics are robust—operating margin of 27.4% and net margin of 21.8%—but are offset by elevated leverage (debt-to-equity of 67.7%) and a quick ratio of 0.689, signaling reliance on inventory conversion and receivables collection for liquidity. The ROE of 26.4% demonstrates strong returns on shareholder capital, though the PEG ratio of 4.88 suggests the market is pricing in growth expectations that may not be fully supported by near-term earnings expansion. The current ratio of 1.025 indicates minimal working capital cushion, a consideration for investors monitoring financial stability.
The bottom line
Johnson & Johnson presents a classic large-cap healthcare trade-off: a mature, profitable business with strong margins and dividend income, but trading at a valuation premium with elevated leverage and modest liquidity buffers. Key factors to weigh include the sustainability of pricing power amid patent expirations and biosimilar competition, the company's ability to service debt and fund R&D in a higher-rate environment, and whether forward earnings growth justifies the current P/E multiple. Investors should monitor quarterly earnings, pipeline progress in key therapeutic areas, and debt refinancing activity to assess whether valuation and financial risk remain aligned with long-term prospects.
Frequently asked questions
What does Johnson & Johnson do?
JNJ operates in two segments: Innovative Medicine, which develops and sells prescription drugs for oncology, immunology, neuroscience, and infectious diseases; and MedTech, which manufactures surgical instruments, orthopedic implants, and cardiovascular devices sold to hospitals and healthcare professionals worldwide.
Is JNJ a dividend stock?
Yes, JNJ pays a dividend with a yield of 2.04% and a payout ratio of 60%, meaning the company distributes a meaningful portion of earnings to shareholders while retaining capital for R&D and growth. JNJ has a long history of consistent dividend payments and increases.
Is JNJ overvalued?
JNJ trades at a trailing P/E of 30.5 and forward P/E of 20.7, which are elevated relative to historical averages and the broader market, though typical for large-cap defensive healthcare stocks. A PEG ratio of 4.88 suggests the valuation may not fully reflect near-term earnings growth, a consideration for value-focused investors.
What are the main risks to JNJ stock?
Key risks include patent expirations and biosimilar competition in pharmaceuticals, elevated debt-to-equity leverage of 67.7%, a quick ratio of 0.689 indicating tight short-term liquidity, and valuation sensitivity to changes in interest rates and earnings growth expectations.
How profitable is Johnson & Johnson?
JNJ demonstrates strong profitability with a gross margin of 68%, operating margin of 27.4%, net margin of 21.8%, and ROE of 26.4%, reflecting pricing power, operational efficiency, and effective capital deployment in mature pharmaceutical and device markets.
What is JNJ's debt situation?
JNJ has a debt-to-equity ratio of 67.7% and a current ratio of 1.025, indicating significant leverage and minimal working capital cushion. The company's strong cash generation and profitability support debt service, but investors should monitor refinancing needs in a higher-rate environment.
Research JNJ with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.